reweave: merge 52 files via frontmatter union [auto]
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
This commit is contained in:
Teleo Agents
parent
26df9beab3
commit
cc4ddda712
52 changed files with 279 additions and 264 deletions
|
|
@ -9,14 +9,14 @@ secondary_domains:
|
|||
- space-development
|
||||
- critical-systems
|
||||
depends_on:
|
||||
- "AI compute demand is creating a terrestrial power crisis with 140 GW of new data center load against grid infrastructure already projected to fall 6 GW short by 2027"
|
||||
- "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
|
||||
- AI compute demand is creating a terrestrial power crisis with 140 GW of new data center load against grid infrastructure already projected to fall 6 GW short by 2027
|
||||
- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
|
||||
related:
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
|
||||
- "AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles"
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
|
||||
- AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles
|
||||
reweave_edges:
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04"
|
||||
- "AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles|related|2026-04-04"
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04
|
||||
- AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles|related|2026-04-04
|
||||
---
|
||||
|
||||
# Arctic and nuclear-powered data centers solve the same power and cooling constraints as orbital compute without launch costs radiation or bandwidth limitations
|
||||
|
|
|
|||
|
|
@ -6,12 +6,12 @@ confidence: likely
|
|||
source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026)"
|
||||
created: 2026-03-07
|
||||
supports:
|
||||
- "consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping"
|
||||
- consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping
|
||||
reweave_edges:
|
||||
- "consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping|supports|2026-03-28"
|
||||
- "tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04"
|
||||
- consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping|supports|2026-03-28
|
||||
- tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04
|
||||
related:
|
||||
- "tempo pilot creates medicare digital health pathway while medicaid coverage contracts"
|
||||
- tempo pilot creates medicare digital health pathway while medicaid coverage contracts
|
||||
---
|
||||
|
||||
# CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo
|
||||
|
|
|
|||
|
|
@ -6,22 +6,22 @@ created: 2026-02-17
|
|||
source: "Grand View Research GLP-1 market analysis 2025; CNBC Lilly/Novo earnings reports; PMC weight regain meta-analyses 2025; KFF Medicare GLP-1 cost modeling; Epic Research discontinuation data"
|
||||
confidence: likely
|
||||
related:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
|
||||
reweave_edges:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31"
|
||||
- "glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics|supports|2026-03-31"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04"
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04"
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31
|
||||
- glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics|supports|2026-03-31
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04
|
||||
supports:
|
||||
- "glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics"
|
||||
- glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: causal
|
|||
sourcer: ECRI
|
||||
related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]", "[[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
|
||||
supports:
|
||||
- "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026"
|
||||
- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
|
||||
reweave_edges:
|
||||
- "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|supports|2026-04-04"
|
||||
- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: structural
|
|||
sourcer: npj Digital Medicine
|
||||
related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
|
||||
supports:
|
||||
- "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks"
|
||||
- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
|
||||
reweave_edges:
|
||||
- "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04"
|
||||
- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
|
||||
|
|
|
|||
|
|
@ -11,11 +11,11 @@ scope: structural
|
|||
sourcer: "Covington & Burling LLP"
|
||||
related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
|
||||
related:
|
||||
- "FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable"
|
||||
- "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026"
|
||||
- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable
|
||||
- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
|
||||
reweave_edges:
|
||||
- "FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03"
|
||||
- "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04"
|
||||
- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03
|
||||
- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04
|
||||
---
|
||||
|
||||
# FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: structural
|
|||
sourcer: npj Digital Medicine authors
|
||||
related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]", "[[ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone]]"]
|
||||
supports:
|
||||
- "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks"
|
||||
- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
|
||||
reweave_edges:
|
||||
- "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04"
|
||||
- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects
|
||||
|
|
|
|||
|
|
@ -6,14 +6,14 @@ confidence: likely
|
|||
source: "NEJM FLOW Trial kidney outcomes, Nature Medicine SGLT2 combination analysis"
|
||||
created: 2026-03-11
|
||||
related:
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
|
||||
- "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator"
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
|
||||
- semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator
|
||||
reweave_edges:
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04"
|
||||
- "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator|related|2026-04-04"
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|supports|2026-04-04"
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04
|
||||
- semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator|related|2026-04-04
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|supports|2026-04-04
|
||||
supports:
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
|
||||
---
|
||||
|
||||
# GLP-1 multi-organ protection creates compounding value across kidney cardiovascular and metabolic endpoints simultaneously rather than treating conditions in isolation
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "Two-year real-world data shows only 15% of non-diabetic obesity pa
|
|||
confidence: likely
|
||||
source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
|
||||
created: 2026-03-11
|
||||
depends_on: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
|
||||
depends_on:
|
||||
- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
|
||||
challenges:
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
|
||||
reweave_edges:
|
||||
- "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04"
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04
|
||||
---
|
||||
|
||||
# GLP-1 persistence drops to 15 percent at two years for non-diabetic obesity patients undermining chronic use economics
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: structural
|
|||
sourcer: RGA (Reinsurance Group of America)
|
||||
related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
|
||||
supports:
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
|
||||
reweave_edges:
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04"
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
|
||||
|
|
|
|||
|
|
@ -12,12 +12,12 @@ attribution:
|
|||
- handle: "jacc-data-report-authors"
|
||||
context: "JACC Data Report 2025, JACC Cardiovascular Statistics 2026, Hypertension journal 2000-2019 analysis"
|
||||
related:
|
||||
- "racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms"
|
||||
- racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms
|
||||
reweave_edges:
|
||||
- "racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms|related|2026-04-03"
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
|
||||
- racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms|related|2026-04-03
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
|
||||
supports:
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
|
||||
---
|
||||
|
||||
# Hypertension-related cardiovascular mortality nearly doubled in the United States 2000–2023 despite the availability of effective affordable generic antihypertensives indicating that hypertension management failure is a behavioral and social determinants problem not a pharmacological availability problem
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: causal
|
|||
sourcer: Yan et al. / JACC
|
||||
related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
|
||||
supports:
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
|
||||
reweave_edges:
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
|
||||
|
|
@ -24,4 +24,3 @@ The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAM
|
|||
*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
|
||||
|
||||
AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend.
|
||||
|
||||
|
|
|
|||
|
|
@ -6,18 +6,18 @@ confidence: experimental
|
|||
source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
|
||||
created: 2026-03-11
|
||||
related:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
|
||||
- "pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
|
||||
- pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
|
||||
reweave_edges:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31"
|
||||
- "pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling|related|2026-03-31"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31
|
||||
- pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling|related|2026-03-31
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
|
||||
supports:
|
||||
- "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
|
||||
---
|
||||
|
||||
# Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence
|
||||
|
|
|
|||
|
|
@ -6,12 +6,12 @@ created: 2026-02-20
|
|||
source: "Braveman & Egerter 2019, Schroeder 2007, County Health Rankings, Dever 1976"
|
||||
confidence: proven
|
||||
supports:
|
||||
- "hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure"
|
||||
- hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
|
||||
reweave_edges:
|
||||
- "hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31"
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04"
|
||||
- hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04
|
||||
related:
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
|
||||
---
|
||||
|
||||
# medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
|
||||
|
|
|
|||
|
|
@ -6,11 +6,11 @@ confidence: likely
|
|||
source: "UK Parliament Public Accounts Committee, BMA, NHS England (2024-2025)"
|
||||
created: 2025-01-15
|
||||
supports:
|
||||
- "gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks"
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
|
||||
- gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
|
||||
reweave_edges:
|
||||
- "gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks|supports|2026-03-31"
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|supports|2026-04-04"
|
||||
- gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks|supports|2026-03-31
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|supports|2026-04-04
|
||||
---
|
||||
|
||||
# NHS demonstrates universal coverage without adequate funding produces excellent primary care but catastrophic specialty access
|
||||
|
|
|
|||
|
|
@ -11,11 +11,11 @@ scope: structural
|
|||
sourcer: npj Digital Medicine
|
||||
related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
|
||||
supports:
|
||||
- "Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate"
|
||||
- "Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects"
|
||||
- Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
|
||||
- Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects
|
||||
reweave_edges:
|
||||
- "Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate|supports|2026-04-04"
|
||||
- "Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects|supports|2026-04-04"
|
||||
- Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate|supports|2026-04-04
|
||||
- Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects|supports|2026-04-04
|
||||
---
|
||||
|
||||
# No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
|
||||
|
|
|
|||
|
|
@ -6,9 +6,9 @@ confidence: likely
|
|||
source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
|
||||
created: 2026-03-11
|
||||
related:
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
|
||||
reweave_edges:
|
||||
- "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04"
|
||||
- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04
|
||||
---
|
||||
|
||||
# Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x
|
||||
|
|
|
|||
|
|
@ -6,12 +6,12 @@ confidence: proven
|
|||
source: "NEJM FLOW Trial (N=3,533, stopped early for efficacy), FDA indication expansion 2024"
|
||||
created: 2026-03-11
|
||||
supports:
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
|
||||
reweave_edges:
|
||||
- "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|supports|2026-03-31"
|
||||
- "semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x|related|2026-04-04"
|
||||
- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|supports|2026-03-31
|
||||
- semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x|related|2026-04-04
|
||||
related:
|
||||
- "semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x"
|
||||
- semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x
|
||||
---
|
||||
|
||||
# Semaglutide reduces kidney disease progression by 24 percent and delays dialysis onset creating the largest per-patient cost savings of any GLP-1 indication because dialysis costs $90K+ per year
|
||||
|
|
|
|||
|
|
@ -6,9 +6,9 @@ created: 2026-02-17
|
|||
source: "FDA January 2026 guidance update on CDS and general wellness; TEMPO pilot (Federal Register December 2025); Faegre Drinker analysis"
|
||||
confidence: likely
|
||||
related:
|
||||
- "tempo pilot creates medicare digital health pathway while medicaid coverage contracts"
|
||||
- tempo pilot creates medicare digital health pathway while medicaid coverage contracts
|
||||
reweave_edges:
|
||||
- "tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04"
|
||||
- tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04
|
||||
---
|
||||
|
||||
# the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification
|
||||
|
|
|
|||
|
|
@ -6,9 +6,9 @@ source: "Architectural Investing, Ch. Epidemiological Transition; Wilkinson (199
|
|||
confidence: likely
|
||||
created: 2026-02-28
|
||||
related:
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
|
||||
reweave_edges:
|
||||
- "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04"
|
||||
- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04
|
||||
---
|
||||
|
||||
# the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: causal
|
|||
sourcer: Yan et al. / JACC
|
||||
related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
|
||||
supports:
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
|
||||
reweave_edges:
|
||||
- "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
|
||||
- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
|
||||
---
|
||||
|
||||
# US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
|
||||
|
|
@ -24,4 +24,3 @@ The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjus
|
|||
*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
|
||||
|
||||
2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation.
|
||||
|
||||
|
|
|
|||
|
|
@ -6,13 +6,13 @@ created: 2026-02-17
|
|||
source: "HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022"
|
||||
confidence: likely
|
||||
related:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
|
||||
- "home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
|
||||
- home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
|
||||
reweave_edges:
|
||||
- "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
|
||||
- "home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift|related|2026-03-31"
|
||||
- "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
|
||||
- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
|
||||
- home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift|related|2026-03-31
|
||||
- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
|
||||
---
|
||||
|
||||
# value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
|
||||
|
|
|
|||
|
|
@ -6,12 +6,12 @@ confidence: likely
|
|||
source: "Astra, Axiom Space research profile February 2026"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030"
|
||||
- "the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit"
|
||||
- commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
|
||||
- the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
|
||||
related:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
|
||||
reweave_edges:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
|
||||
---
|
||||
|
||||
# Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "Bezos funds $14B+ to build launch, landers, stations, and comms co
|
|||
confidence: experimental
|
||||
source: "Astra, Blue Origin research profile February 2026"
|
||||
created: 2026-03-20
|
||||
challenged_by: ["historically slow execution and total Bezos dependency — two successful New Glenn flights is a start not a pattern"]
|
||||
challenged_by:
|
||||
- historically slow execution and total Bezos dependency — two successful New Glenn flights is a start not a pattern
|
||||
related:
|
||||
- "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability"
|
||||
- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
|
||||
reweave_edges:
|
||||
- "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04"
|
||||
- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
|
||||
---
|
||||
|
||||
# Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services
|
||||
|
|
|
|||
|
|
@ -5,13 +5,14 @@ description: "SpaceX uses Starlink demand to drive launch cadence which drives r
|
|||
confidence: likely
|
||||
source: "Astra synthesis from SpaceX 2025 financials ($19B revenue, ~$2B net income), Starlink subscriber data (10M), launch cadence data (170 launches in 2025), Falcon 9 booster reuse records (32 flights on single first stage)"
|
||||
created: 2026-03-07
|
||||
challenged_by: "The flywheel thesis assumes Starlink revenue growth continues and that the broadband market sustains the cadence needed for reusability learning. Starlink faces regulatory barriers in several countries, spectrum allocation conflicts, and potential competition from non-LEO broadband (5G/6G terrestrial expansion). If Starlink growth plateaus, the flywheel loses its demand driver. Also, the xAI merger introduces execution complexity that could distract from launch operations."
|
||||
challenged_by:
|
||||
- The flywheel thesis assumes Starlink revenue growth continues and that the broadband market sustains the cadence needed for reusability learning. Starlink faces regulatory barriers in several countries, spectrum allocation conflicts, and potential competition from non-LEO broadband (5G/6G terrestrial expansion). If Starlink growth plateaus, the flywheel loses its demand driver. Also, the xAI merger introduces execution complexity that could distract from launch operations.
|
||||
related:
|
||||
- "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability"
|
||||
- "varda vertical integration reduces space manufacturing access costs"
|
||||
- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
|
||||
- varda vertical integration reduces space manufacturing access costs
|
||||
reweave_edges:
|
||||
- "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04"
|
||||
- "varda vertical integration reduces space manufacturing access costs|related|2026-04-04"
|
||||
- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
|
||||
- varda vertical integration reduces space manufacturing access costs|related|2026-04-04
|
||||
---
|
||||
|
||||
# SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
|
||||
|
|
|
|||
|
|
@ -6,16 +6,16 @@ confidence: experimental
|
|||
source: "Astra, web research compilation including CNBC, GeekWire, DCD, IEEE Spectrum, TechCrunch February 2026"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players"
|
||||
- "on-orbit processing of satellite data is the proven near-term use case for space compute because it avoids bandwidth and thermal bottlenecks simultaneously"
|
||||
- "SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"
|
||||
- orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players
|
||||
- on-orbit processing of satellite data is the proven near-term use case for space compute because it avoids bandwidth and thermal bottlenecks simultaneously
|
||||
- SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
|
||||
related:
|
||||
- "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale"
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
|
||||
reweave_edges:
|
||||
- "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|related|2026-04-04"
|
||||
- "Starcloud|supports|2026-04-04"
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|related|2026-04-04
|
||||
- Starcloud|supports|2026-04-04
|
||||
supports:
|
||||
- "Starcloud"
|
||||
- Starcloud
|
||||
---
|
||||
|
||||
# Starcloud is the first company to operate a datacenter-grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million-satellite constellation
|
||||
|
|
|
|||
|
|
@ -5,15 +5,16 @@ description: "Model A (water for orbital propellant) closes at $10K-50K/kg avoid
|
|||
confidence: likely
|
||||
source: "Astra, web research compilation February 2026"
|
||||
created: 2026-03-20
|
||||
challenged_by: ["falling launch costs may undercut Model A economics if Earth-launched water becomes cheaper than asteroid-derived water"]
|
||||
challenged_by:
|
||||
- falling launch costs may undercut Model A economics if Earth-launched water becomes cheaper than asteroid-derived water
|
||||
related:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
|
||||
- "the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
|
||||
- the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining
|
||||
reweave_edges:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04"
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
|
||||
- "the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining|related|2026-04-04"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
|
||||
- the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining|related|2026-04-04
|
||||
---
|
||||
|
||||
# Asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away
|
||||
|
|
|
|||
|
|
@ -6,11 +6,11 @@ confidence: likely
|
|||
source: "Astra, web research compilation February 2026; NASA TRL assessments"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "asteroid mining second wave succeeds where the first failed because launch costs fell 10x spacecraft costs fell 30x and real customers now exist"
|
||||
- asteroid mining second wave succeeds where the first failed because launch costs fell 10x spacecraft costs fell 30x and real customers now exist
|
||||
related:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
|
||||
reweave_edges:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04
|
||||
---
|
||||
|
||||
# Asteroid mining technology readiness drops sharply after prospecting with anchoring at TRL 2-3 and zero-gravity refining at TRL 1-2
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "Axiom (PPTM launching 2027), Vast (Haven-1 slipped to Q1 2027), St
|
|||
confidence: likely
|
||||
source: "Astra synthesis from NASA Commercial LEO Destinations program, Axiom Space funding ($605M+), Vast Haven-1 timeline, ISS Deorbit Vehicle contract ($843M to SpaceX), MIT Technology Review 2026 Breakthrough Technologies"
|
||||
created: 2026-03-08
|
||||
challenged_by: "Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years."
|
||||
challenged_by:
|
||||
- Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years.
|
||||
supports:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
|
||||
reweave_edges:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
|
||||
---
|
||||
|
||||
# commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: structural
|
|||
sourcer: National Defense Magazine
|
||||
related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
|
||||
supports:
|
||||
- "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks"
|
||||
- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks
|
||||
reweave_edges:
|
||||
- "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04"
|
||||
- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing
|
||||
|
|
|
|||
|
|
@ -7,9 +7,9 @@ source: "German Aerospace Center (DLR) assessment via Phys.org, March 2026"
|
|||
created: 2026-03-11
|
||||
secondary_domains: [grand-strategy]
|
||||
related:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
|
||||
reweave_edges:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
|
||||
---
|
||||
|
||||
# European aerospace institutions assess that Starship-class capability is strategically necessary, not merely advantageous
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "Starship at $10-100/kg makes ISRU prospecting missions viable but
|
|||
confidence: likely
|
||||
source: "Astra synthesis from Falcon 9 vs Starship cost trajectories, orbital mechanics delta-v budgets, ISRU cost modeling"
|
||||
created: 2026-03-07
|
||||
challenged_by: "The geographic resolution may be too clean. Even at lunar distances, if Starship achieves the low end of cost projections ($10-30/kg to LEO), the additional delta-v cost to deliver water to the lunar surface from Earth may be competitive with extracting it locally — especially if lunar ISRU requires heavy upfront infrastructure investment that amortizes slowly."
|
||||
challenged_by:
|
||||
- The geographic resolution may be too clean. Even at lunar distances, if Starship achieves the low end of cost projections ($10-30/kg to LEO), the additional delta-v cost to deliver water to the lunar surface from Earth may be competitive with extracting it locally — especially if lunar ISRU requires heavy upfront infrastructure investment that amortizes slowly.
|
||||
related:
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
|
||||
reweave_edges:
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
|
||||
---
|
||||
|
||||
# falling launch costs paradoxically both enable and threaten in-space resource utilization by making infrastructure affordable while competing with the end product
|
||||
|
|
|
|||
|
|
@ -11,11 +11,11 @@ scope: causal
|
|||
sourcer: "Air & Space Forces Magazine"
|
||||
related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]", "[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]"]
|
||||
supports:
|
||||
- "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible"
|
||||
- "The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale"
|
||||
- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible
|
||||
- The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale
|
||||
reweave_edges:
|
||||
- "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04"
|
||||
- "The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale|supports|2026-04-04"
|
||||
- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04
|
||||
- The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception
|
||||
|
|
|
|||
|
|
@ -11,11 +11,11 @@ scope: structural
|
|||
sourcer: Breaking Defense
|
||||
related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]"]
|
||||
supports:
|
||||
- "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception"
|
||||
- "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks"
|
||||
- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception
|
||||
- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks
|
||||
reweave_edges:
|
||||
- "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04"
|
||||
- "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04"
|
||||
- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04
|
||||
- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible
|
||||
|
|
|
|||
|
|
@ -6,16 +6,16 @@ confidence: likely
|
|||
source: "Astra, web research compilation February 2026"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "attractor states provide gravitational reference points for capital allocation during structural industry change"
|
||||
- attractor states provide gravitational reference points for capital allocation during structural industry change
|
||||
secondary_domains:
|
||||
- teleological-economics
|
||||
related:
|
||||
- "gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity"
|
||||
- gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity
|
||||
reweave_edges:
|
||||
- "gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity|related|2026-04-04"
|
||||
- "the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next|supports|2026-04-04"
|
||||
- gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity|related|2026-04-04
|
||||
- the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next|supports|2026-04-04
|
||||
supports:
|
||||
- "the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next"
|
||||
- the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next
|
||||
---
|
||||
|
||||
# launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds
|
||||
|
|
|
|||
|
|
@ -11,11 +11,11 @@ scope: structural
|
|||
sourcer: Breaking Defense
|
||||
related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
|
||||
supports:
|
||||
- "Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing"
|
||||
- "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible"
|
||||
- Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing
|
||||
- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible
|
||||
reweave_edges:
|
||||
- "Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing|supports|2026-04-04"
|
||||
- "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04"
|
||||
- Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing|supports|2026-04-04
|
||||
- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks
|
||||
|
|
|
|||
|
|
@ -8,23 +8,23 @@ created: 2026-02-17
|
|||
secondary_domains:
|
||||
- critical-systems
|
||||
depends_on:
|
||||
- "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
|
||||
- "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
|
||||
- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
|
||||
- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
|
||||
supports:
|
||||
- "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation"
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
|
||||
- "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale"
|
||||
- "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved"
|
||||
- "Starcloud"
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
|
||||
- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved
|
||||
- Starcloud
|
||||
reweave_edges:
|
||||
- "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04"
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|supports|2026-04-04"
|
||||
- "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04"
|
||||
- "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04"
|
||||
- "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|supports|2026-04-04"
|
||||
- "Starcloud|supports|2026-04-04"
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|supports|2026-04-04
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04
|
||||
- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04
|
||||
- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|supports|2026-04-04
|
||||
- Starcloud|supports|2026-04-04
|
||||
related:
|
||||
- "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling"
|
||||
- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling
|
||||
---
|
||||
|
||||
# Orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players
|
||||
|
|
|
|||
|
|
@ -6,15 +6,15 @@ confidence: likely
|
|||
source: "Astra, space data centers feasibility analysis February 2026; Google Project Suncatcher analysis"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
|
||||
- "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
|
||||
- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
|
||||
- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
|
||||
challenges:
|
||||
- "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation"
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
|
||||
reweave_edges:
|
||||
- "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|challenges|2026-04-04"
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04"
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|challenges|2026-04-04
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04
|
||||
related:
|
||||
- "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
|
||||
- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
|
||||
---
|
||||
|
||||
# Orbital data centers require five enabling technologies to mature simultaneously and none currently exist at required readiness
|
||||
|
|
|
|||
|
|
@ -6,11 +6,11 @@ confidence: proven
|
|||
source: "NASA Space Shuttle program cost data ($1.5B per launch, 27,500 kg payload, $54,500/kg over 30 years of operations), SpaceX Falcon 9 reuse economics for contrast"
|
||||
created: 2026-03-07
|
||||
related:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
|
||||
- "europe space launch strategic irrelevance without starship class capability"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
|
||||
- europe space launch strategic irrelevance without starship class capability
|
||||
reweave_edges:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
|
||||
- "europe space launch strategic irrelevance without starship class capability|related|2026-04-04"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
|
||||
- europe space launch strategic irrelevance without starship class capability|related|2026-04-04
|
||||
---
|
||||
|
||||
# reusability without rapid turnaround and minimal refurbishment does not reduce launch costs as the Space Shuttle proved over 30 years
|
||||
|
|
|
|||
|
|
@ -7,12 +7,12 @@ source: "European reusable launch program status via Phys.org, March 2026"
|
|||
created: 2026-03-11
|
||||
secondary_domains: [grand-strategy]
|
||||
related:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
|
||||
reweave_edges:
|
||||
- "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
|
||||
- "europe space launch strategic irrelevance without starship class capability|supports|2026-04-04"
|
||||
- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
|
||||
- europe space launch strategic irrelevance without starship class capability|supports|2026-04-04
|
||||
supports:
|
||||
- "europe space launch strategic irrelevance without starship class capability"
|
||||
- europe space launch strategic irrelevance without starship class capability
|
||||
---
|
||||
|
||||
# Reusability in heavy-lift launch may create a capability divide between operational programs and concept-stage competitors rather than diffusing globally
|
||||
|
|
|
|||
|
|
@ -11,9 +11,9 @@ scope: structural
|
|||
sourcer: National Defense Magazine
|
||||
related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]"]
|
||||
supports:
|
||||
- "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception"
|
||||
- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception
|
||||
reweave_edges:
|
||||
- "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04"
|
||||
- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04
|
||||
---
|
||||
|
||||
# The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale
|
||||
|
|
|
|||
|
|
@ -8,16 +8,16 @@ created: 2026-02-17
|
|||
secondary_domains:
|
||||
- critical-systems
|
||||
depends_on:
|
||||
- "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
|
||||
- "power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited"
|
||||
- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
|
||||
- power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited
|
||||
related:
|
||||
- "Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale"
|
||||
- "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling"
|
||||
- "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved"
|
||||
- Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale
|
||||
- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling
|
||||
- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved
|
||||
reweave_edges:
|
||||
- "Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale|related|2026-04-04"
|
||||
- "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04"
|
||||
- "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|related|2026-04-04"
|
||||
- Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale|related|2026-04-04
|
||||
- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04
|
||||
- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|related|2026-04-04
|
||||
---
|
||||
|
||||
# Space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
|
||||
|
|
|
|||
|
|
@ -8,12 +8,12 @@ created: 2026-02-17
|
|||
secondary_domains:
|
||||
- health
|
||||
depends_on:
|
||||
- "microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors"
|
||||
- "microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods"
|
||||
- microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors
|
||||
- microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods
|
||||
supports:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
|
||||
reweave_edges:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Space-based pharmaceutical manufacturing produces clinically superior drug formulations that cannot be replicated on Earth
|
||||
|
|
|
|||
|
|
@ -6,11 +6,12 @@ confidence: likely
|
|||
source: "Astra, Space Ambition / Beyond Earth Technologies 2024 deal analysis (65 deals >$5M)"
|
||||
created: 2026-03-23
|
||||
secondary_domains: ["manufacturing"]
|
||||
challenged_by: ["growing institutional interest (Axiom $350M, CesiumAstro $270M in early 2026) may be closing the gap as the sector matures"]
|
||||
challenged_by:
|
||||
- growing institutional interest (Axiom $350M, CesiumAstro $270M in early 2026) may be closing the gap as the sector matures
|
||||
related:
|
||||
- "aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets"
|
||||
- aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets
|
||||
reweave_edges:
|
||||
- "aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets|related|2026-04-04"
|
||||
- aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets|related|2026-04-04
|
||||
---
|
||||
|
||||
# SpaceTech Series A+ funding gap is the structural bottleneck because specialized VCs concentrate at seed while generalists lack domain expertise for hardware companies
|
||||
|
|
|
|||
|
|
@ -6,11 +6,11 @@ confidence: likely
|
|||
source: "Astra, web research compilation February 2026; orbital mechanics literature"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away"
|
||||
- asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away
|
||||
supports:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
|
||||
reweave_edges:
|
||||
- "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|supports|2026-04-04"
|
||||
- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Ten percent of near-Earth asteroids are more energetically accessible than the lunar surface with some requiring less delta-v than a soft Moon landing
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "61 nations signed bilateral accords establishing resource extracti
|
|||
confidence: likely
|
||||
source: "Artemis Accords text (2020), signatory count (61 as of January 2026), US State Department bilateral framework, comparison with Moon Agreement ratification failure"
|
||||
created: 2026-03-08
|
||||
challenged_by: "The Accords may be less durable than treaties because they lack binding enforcement. If a signatory violates safety zone norms or resource extraction principles, no mechanism compels compliance. The bilateral structure also means each agreement is slightly different, creating potential inconsistencies that multilateral treaties avoid. And the China/Russia exclusion creates a bifurcated governance regime that could escalate into resource conflicts at contested sites like the lunar south pole."
|
||||
challenged_by:
|
||||
- The Accords may be less durable than treaties because they lack binding enforcement. If a signatory violates safety zone norms or resource extraction principles, no mechanism compels compliance. The bilateral structure also means each agreement is slightly different, creating potential inconsistencies that multilateral treaties avoid. And the China/Russia exclusion creates a bifurcated governance regime that could escalate into resource conflicts at contested sites like the lunar south pole.
|
||||
supports:
|
||||
- "lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment"
|
||||
- lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment
|
||||
reweave_edges:
|
||||
- "lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment|supports|2026-04-04"
|
||||
- lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment|supports|2026-04-04
|
||||
---
|
||||
|
||||
# the Artemis Accords replace multilateral treaty-making with bilateral norm-setting to create governance through coalition practice rather than universal consensus
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "SpaceX pivoted near-term focus from Mars to Moon in February 2026
|
|||
confidence: likely
|
||||
source: "Astra, SpaceX announcements and web research February 2026"
|
||||
created: 2026-03-20
|
||||
challenged_by: ["lunar environment differs fundamentally from Mars — 1/6g vs 1/3g, no atmosphere, different regolith chemistry — so lunar-proven systems may need significant redesign for Mars"]
|
||||
challenged_by:
|
||||
- lunar environment differs fundamentally from Mars — 1/6g vs 1/3g, no atmosphere, different regolith chemistry — so lunar-proven systems may need significant redesign for Mars
|
||||
related:
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
|
||||
reweave_edges:
|
||||
- "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
|
||||
- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
|
||||
---
|
||||
|
||||
# The Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey
|
||||
|
|
|
|||
|
|
@ -6,11 +6,11 @@ confidence: likely
|
|||
source: "Astra, web research compilation February 2026"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030"
|
||||
- commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
|
||||
related:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
|
||||
reweave_edges:
|
||||
- "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04"
|
||||
- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
|
||||
---
|
||||
|
||||
# The commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
|
||||
|
|
|
|||
|
|
@ -6,15 +6,15 @@ confidence: likely
|
|||
source: "Astra, web research compilation February 2026"
|
||||
created: 2026-02-17
|
||||
depends_on:
|
||||
- "launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds"
|
||||
- "good management causes disruption because rational resource allocation systematically favors sustaining innovation over disruptive opportunities"
|
||||
- launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds
|
||||
- good management causes disruption because rational resource allocation systematically favors sustaining innovation over disruptive opportunities
|
||||
secondary_domains:
|
||||
- teleological-economics
|
||||
- critical-systems
|
||||
supports:
|
||||
- "europe space launch strategic irrelevance without starship class capability"
|
||||
- europe space launch strategic irrelevance without starship class capability
|
||||
reweave_edges:
|
||||
- "europe space launch strategic irrelevance without starship class capability|supports|2026-04-04"
|
||||
- europe space launch strategic irrelevance without starship class capability|supports|2026-04-04
|
||||
---
|
||||
|
||||
# the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport
|
||||
|
|
|
|||
|
|
@ -6,13 +6,14 @@ description: "Varda's monoclonal antibody processing starting in 2026 suggests c
|
|||
confidence: experimental
|
||||
source: "Varda Space Industries PR (2026-01-29), new biologics lab opening"
|
||||
created: 2026-01-29
|
||||
depends_on: ["the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure"]
|
||||
depends_on:
|
||||
- the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure
|
||||
related:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
|
||||
- "varda vertical integration reduces space manufacturing access costs"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
|
||||
- varda vertical integration reduces space manufacturing access costs
|
||||
reweave_edges:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|related|2026-04-04"
|
||||
- "varda vertical integration reduces space manufacturing access costs|related|2026-04-04"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|related|2026-04-04
|
||||
- varda vertical integration reduces space manufacturing access costs|related|2026-04-04
|
||||
---
|
||||
|
||||
# Varda's biologics development suggests companies may pursue parallel tier development in space manufacturing
|
||||
|
|
|
|||
|
|
@ -5,11 +5,12 @@ description: "In-house satellite bus and heatshield production enables Varda to
|
|||
confidence: experimental
|
||||
source: "Varda Space Industries W-5 mission (2026-01-29), vertical integration debut"
|
||||
created: 2026-01-29
|
||||
depends_on: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"]
|
||||
depends_on:
|
||||
- SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
|
||||
supports:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
|
||||
reweave_edges:
|
||||
- "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04"
|
||||
- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Varda's vertical integration of satellite bus and ablative heatshield enables cost reduction and accelerated iteration in reentry vehicle design
|
||||
|
|
|
|||
|
|
@ -9,6 +9,12 @@ industry: orbital data centers, space-based AI compute
|
|||
key_people: []
|
||||
website: []
|
||||
tags: [orbital-data-center, AI-compute, small-satellite, NVIDIA-partnership, SpaceX-rideshare]
|
||||
supports:
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
|
||||
reweave_edges:
|
||||
- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04
|
||||
- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04
|
||||
---
|
||||
|
||||
# Starcloud
|
||||
|
|
|
|||
Loading…
Reference in a new issue